Justin Kim
Stock Analyst at Oppenheimer
(4.35)
# 1,311
Out of 4,698 analysts
102
Total ratings
50%
Success rate
14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Reiterated: Buy | $15 → $16 | $6.23 | +156.82% | 4 | Jun 8, 2026 | |
| IONS Ionis Pharmaceuticals | Rated: Buy | $63 → $110 | $58.09 | +89.36% | 6 | Apr 30, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $85 → $86 | $36.13 | n/a | 10 | May 8, 2025 | |
| CYTK Cytokinetics | Maintained: Buy | $54 → $96 | $72.72 | n/a | 10 | Feb 28, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterated: Buy | $12 | $1.48 | n/a | 21 | Oct 3, 2024 | |
| VERA Vera Therapeutics | Reiterated: Buy | $34 | $35.89 | n/a | 1 | Jan 26, 2024 | |
| PHVS Pharvaris | Rated: Buy | $26 | $35.25 | n/a | 8 | Nov 10, 2023 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | n/a | $16.08 | n/a | 28 | Aug 8, 2023 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Hold | n/a | $9.96 | n/a | 6 | Dec 15, 2022 | |
| ELTX Elicio Therapeutics | Downgraded: Hold | n/a | $2.41 | n/a | 8 | Jun 30, 2022 |
Zura Bio
Jun 8, 2026
Reiterated: Buy
Price Target: $15 → $16
Current: $6.23
Upside: +156.82%
Ionis Pharmaceuticals
Apr 30, 2026
Rated: Buy
Price Target: $63 → $110
Current: $58.09
Upside: +89.36%
Immunocore Holdings
May 8, 2025
Maintained: Buy
Price Target: $85 → $86
Current: $36.13
Upside: n/a
Cytokinetics
Feb 28, 2025
Maintained: Buy
Price Target: $54 → $96
Current: $72.72
Upside: n/a
Aldeyra Therapeutics
Oct 3, 2024
Reiterated: Buy
Price Target: $12
Current: $1.48
Upside: n/a
Vera Therapeutics
Jan 26, 2024
Reiterated: Buy
Price Target: $34
Current: $35.89
Upside: n/a
Pharvaris
Nov 10, 2023
Rated: Buy
Price Target: $26
Current: $35.25
Upside: n/a
Aurinia Pharmaceuticals
Aug 8, 2023
Maintained: Hold
Price Target: n/a
Current: $16.08
Upside: n/a
BioCryst Pharmaceuticals
Dec 15, 2022
Maintained: Hold
Price Target: n/a
Current: $9.96
Upside: n/a
Elicio Therapeutics
Jun 30, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.41
Upside: n/a